Compare DexCom, Inc. (DXCM) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tilray Brands Inc — how do they compare? DexCom, Inc. trades at $77.46 (market cap $28.06B), while Tilray Brands Inc trades at $4.34 (market cap $541.36M). The key difference: DexCom, Inc. is far larger — about 51.8× Tilray Brands Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | TLRY | |
|---|---|---|
Market Cap | $28.06B | $541.36M |
Sector | Health | Health |
52-Week High | $89.53 | $21.00 |
52-Week Low | $54.84 | $4.31 |
Enterprise Value | $27.03B | $638.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
TLRY trades at $4.36, down 0.57% on the day, amid a bearish technical signal and mixed quarterly earnings. The company reported a net loss of -$2.19 billion for 2025 despite revenue growth to $821 million, with a negative net income margin of -156.67%. Recent developments include medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
While low valuation ratios (P/S of 0.55, P/B of 0.35) suggest potential undervaluation, persistent losses and negative cash flow from operations pose significant risks. Analyst sentiment is cautious with a 'Hold' consensus, reflecting concerns over profitability despite growth initiatives. The stock's outlook hinges on achieving sustainable profitability and navigating competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
